Nantahala Capital Management’s Fulcrum Therapeutics FULC Stock Holding History

Nantahala Capital Management’s Portfolio FULC Stock Details FULC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$23.4M	Sell	3,050,040 -1,243,306	-29%	-$11.5M	0.86%	30
2025 Q4	$48.6M	Sell	4,293,346 -377,438	-8%	-$3.84M	1.61%	12
2025 Q3	$43M	Buy	4,670,784 +382,485	+9%	+$2.77M	1.49%	14
2025 Q2	$29.5M	Sell	4,288,299 -534,394	-11%	-$2.86M	1.16%	15
2025 Q1	$13.9M	Buy	4,822,693 +42,985	+0.9%	+$158K	0.55%	30
2024 Q4	$22.5M	Buy	4,779,708 +1,796	+0%	+$6.63K	0.96%	19
2024 Q3	$17.1M	Buy	+4,777,912	New	+$35.4M	0.86%	25
2023 Q3	–	Sell	-21,370	Closed	-$70.5K	–	139
2023 Q2	$70.5K	Hold	21,370	–	–	0.01%	119
2023 Q1	$60.9K	Sell	21,370 -478,630	-96%	-$4.29M	﹤0.01%	120
2022 Q4	$3.64M	Buy	+500,000	New	+$3.26M	0.24%	58

Other funds holding FULC

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

FTM

First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Nantahala Capital Management's FULC Position: Q1 2026 in Review

Nantahala Capital Management reduced its Fulcrum Therapeutics (FULC) stake by 29% in Q1 2026, selling an estimated $11.5M and leaving 3,050,040 shares worth $23.4M. The position accounts for 0.86% of the portfolio, ranked #30.

Nantahala Capital Management first reported a position in FULC in Q4 2022 and has held it in 10 quarters since. The position peaked at $48.6M in Q4 2025. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

Nantahala Capital Management held 3,050,040 shares of Fulcrum Therapeutics worth $23.4M as of Q1 2026.
Nantahala Capital Management sold 1,243,306 Fulcrum Therapeutics shares in Q1 2026, an estimated $11.5M.
Fulcrum Therapeutics made up 0.86% of Nantahala Capital Management's portfolio in Q1 2026, its #30 holding.
Nantahala Capital Management first reported a position in Fulcrum Therapeutics in Q4 2022 and has held it in 10 quarters since.
Nantahala Capital Management's Fulcrum Therapeutics position peaked at $48.6M in Q4 2025.
169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on Nantahala Capital Management's 13F filing for Q1 2026, filed 15 May 2026.